Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2011 / Cilt: 45 - Sayı: 4

Retinopathy of prematurity via neonatology perspective

Neonatoloji bakış açısı ile prematüre retinopatisi

Pages
142–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we discuss risk factors, pathogenesis, management, and available treatments of ROP, with the perspective of neonatology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinopathy of prematurity (ROP) is the major ocular disorder of the neonate that primarily affects premature infants and the dominant cause of severe visual impairment in childhood especially in developing countries.
📊
Key Findings & Data:ROP is a biphasic retinal vascular disease.
💡
Conclusion & Impact:In this review, we discuss risk factors, pathogenesis, management, and available treatments of ROP, with the perspective of neonatology.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinopathy of prematurity (ROP) is the major ocular disorder of the neonate that primarily affects premature infants and the dominant cause of severe visual impairment in childhood especially in developing countries. ROP is a biphasic retinal vascular disease. In the first phase, relative hyperoxia results in vaso-obliteration and vessel loss. The second phase is characterized by hypoxia-induced neovascularization resulting in retinal detachment and blindness. Present therapeutic modalities to limit the adverse consequences of aberrant neovascularization are tissue-destructive. In this review, we discuss risk factors, pathogenesis, management, and available treatments of ROP, with the perspective of neonatology.

Özet

Prematüre retinopatisi (PR) primer olarak prematüre bebekleri etkileyen, özellikle gelişmekte olan ülkelerde çocukluk çağında ağır görme bozukluklarına yol açan önemli bir göz hastalığıdır. Prematüre retinopatisi bifazik patogenezi olan retinal vaskular hastalıktır. İlk fazda, relatif hiperoksi vazo-obliterasyona ve damar hasarına yol açar. İkinci faz hipoksinin tetiklediği retinal ayrılma ve körlükle sonuçlanan neovaskülarizasyon ile karakterizedir. Mevcut tedavi yöntemlerinin amacı anormal neovaskülarizasyonun doku hasarına yol açan olumsuz sonuçlarını sınırlamaktır. Bu derlemede, PR risk faktörleri, patogenez, yaklaşım ve mevcut tedaviler neonatoloji bakış açısı ile tartışıldı.

🔖

Cite This Article

USLU, S., BÜLBÜL, A. (2011). Retinopathy of prematurity via neonatology perspective. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 45 - Sayı: 4, 142–152. https://ajindex.com/articles/364091

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS 1999;3(1):26-32
  2. Madan A, Good WV: Disorders of the eye. In: HW Taeusch, and RA Ballard (eds). Avery’s diseases of the newborn, 8th edition, Philadelphia, Elsevier Saunders, 2005, s 1539-55
  3. Terry TL. Fibroblastic Overgrowth of Persistent Tunica Vasculosa Lentis in Infants Born Prematurely: II. Report of Cases-Clinical Aspects. Trans Am Ophthalmol Soc 1942;40:262-84
  4. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust 1951;2(2):48-50
  5. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84(2):77-82
  6. Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics 1999;104(3):e26
  7. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116(1):15-23
  8. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020—the right to sight. Bull World Health Organ 2001;79(3):227-232
  9. Ergenekon E, Turan Ö, Özdek Ş, Hirfanoğlu İ, Bozkaya D, Önal E, et al. Türkiye’de prematüre retinopatisi sıklığının durumu. Çocuk Sağlığı ve Hastalıkları Dergisi 2010;53(1):4-9
  10. Phelps DL. Retinopathy of Prematurity: History, classification, and pathophysiology. Neo Reviews 2001;2:153-66
  11. Arsan S. Prematüre retinopatisi. T Klin Pediatri 2004;2:382-6
  12. Özkan H, Köksal N. Prematüre retinopatisi. Güncel Pediatri 2005;2(2):24-8
  13. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114(10):1219-28. Erratum in: Arch Ophthalmol 1997;115(3):427
  14. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113(12):1538-44
  15. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246(4935):1309-12
  16. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR- 1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurit